BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 19440559)

  • 1. Molecule of the month. Riociguat.
    Drug News Perspect; 2009 Apr; 22(3):167. PubMed ID: 19440559
    [No Abstract]   [Full Text] [Related]  

  • 2. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
    Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Riociguat for the treatment of pulmonary hypertension.
    Meis T; Behr J
    Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Riociguat - a stimulator of soluble guanylate cyclase: a new mode of action helps patients with pulmonary hypertension].
    Kreutzkamp B
    Med Monatsschr Pharm; 2013 Dec; 36(12):442-7. PubMed ID: 24450268
    [No Abstract]   [Full Text] [Related]  

  • 5. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Mielniczuk LM; Swiston JR; Mehta S
    Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
    Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
    Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
    Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
    Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
    Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
    Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Belik J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Bishop BM
    Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riociguat for the treatment of pulmonary hypertension.
    Hambly N; Granton J
    Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinically Worsening Chronic Thromboembolic Pulmonary Hypertension by Riociguat After Balloon Pulmonary Angioplasty.
    Minatsuki S; Hatano M; Kiyosue A; Saito A; Maki H; Takimoto E; Komuro I
    Int Heart J; 2018 Sep; 59(5):1186-1188. PubMed ID: 30158388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Riociguat (Adempas) for pulmonary hypertension.
    Med Lett Drugs Ther; 2014 Mar; 56(1437):17-9. PubMed ID: 24589497
    [No Abstract]   [Full Text] [Related]  

  • 16. Riociguat approved for pulmonary hypertension.
    Traynor K
    Am J Health Syst Pharm; 2013 Nov; 70(22):1960. PubMed ID: 24173000
    [No Abstract]   [Full Text] [Related]  

  • 17. First-in-class guanylate cyclase stimulator approved for PAH.
    Guha M
    Nat Biotechnol; 2013 Dec; 31(12):1064. PubMed ID: 24316627
    [No Abstract]   [Full Text] [Related]  

  • 18. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Riociguat for pulmonary hypertension.
    Cannon JE; Pepke-Zaba J
    Expert Rev Clin Pharmacol; 2014 May; 7(3):259-70. PubMed ID: 24580082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.